Zenotech Laboratories

Zenotech Laboratories Rule of 40

The Rule of 40 of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -12.89 %. In the previous year, Rule of 40 was 26.66 % — a change of -148.35% (lower).

Rule of 40

-12.89 %

YoY

-148.35%

Last updated:

Rule of 40 of Zenotech Laboratories is 2026 -12.89 % . Rule of 40 of Zenotech Laboratories was 2025 26.66 % . It decreases by -148.35% lower compared to the previous year.

The Zenotech Laboratories Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
-40.35 INR
Jan 1, 2020
139.56 INR
Jan 1, 2021
-25.70 INR
Jan 1, 2022
118.87 INR
Jan 1, 2023
50.47 INR
Jan 1, 2024
21.18 INR
Jan 1, 2025
26.66 INR
Jan 1, 2026
-12.89 INR
The Zenotech Laboratories Rule of 40 history
YEARRule of 40YoY
-12.89 %-148.35%
26.66 %+25.87%
21.18 %-58.03%
50.47 %-57.54%
118.87 %-562.49%
-25.70 %-118.42%
139.56 %-445.85%
-40.35 %-113.95%
289.21 %-152.83%
-547.46 %-5.33%
-578.31 %+103.99%
-283.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Rule of 40 of Zenotech Laboratories is -12.89 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories